Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Abrogating fibrinolysis does not improve bleeding or rFVIIa/rFVIII treatment in a non-mucosal venous injury model in haemophilic rodents.

Journal of thrombosis and haemostasis : JTH - 1 Jul 2018

Stagaard R, Flick M J, Bojko B, Goryński K, Goryńska P Z, Ley C D, Olsen L H, Knudsen T

Abstract excerpt

Essentials The efficacy of systemic antifibrinolytics for hemophilic non-mucosal bleeding is undetermined. The effect of systemically inhibiting fibrinolysis in hemophilic mice and rats was explored. Neither bleeding nor the response to factor treatment was improved after inhibiting fibrinolysis. The non-mucosal bleeding phenotype in hemophilia A appears largely unaffected by fibrinolysis. SUMMARY: Background...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Coagulants
Share to Factor VIIa

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fibrinolysis

Share to Mice, 129 Strain

Share to Plasminogen

Share to Rats, Transgenic

Share to Tissue Plasminogen Activator

Source

Open in PubMed Open full text

Identifiers

PMID: 29758126
DOI: 10.1111/jth.14148
PMCID: PMC8040545

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Abrogating fibrinolysis does not improve bleeding or rFVIIa/rFVIII treatment in a non-mucosal venous injury model in haemophilic rodents.PMID 29758126Read ↗

Pharmacological concentrations of recombinant factor VIIa restore hemostasis independent of tissue factor in antibody-induced hemophilia mice.Semantic proximity Read ↗

The severe spontaneous bleeding phenotype in a novel hemophilia A rat model is rescued by platelet FVIII expression.Semantic proximity Read ↗

Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life.Semantic proximity Read ↗

Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia.Semantic proximity Read ↗

An activated factor VII variant with enhanced tissue factor-independent activity speeds wound healing in a mouse hemophilia B model.Semantic proximity Read ↗

What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse?Semantic proximity Read ↗

Fibrinolysis shutdown phenotype masks changes in rodent coagulation in tissue injury versus hemorrhagic shock.Semantic proximity Read ↗

Systemic or topical application of plasminogen activator inhibitor with extended half-life (VLHL PAI-1) reduces bleeding time and total blood loss.Semantic proximity Read ↗

Targeted inactivation of the mouse locus encoding coagulation factor XIII-A: hemostatic abnormalities in mutant mice and characterization of the coagulation deficit.Semantic proximity Read ↗

Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice.Semantic proximity Read ↗

Effects of plasma kallikrein deficiency on haemostasis and thrombosis in mice: murine ortholog of the Fletcher trait.Semantic proximity Read ↗

A Thrombin-Activatable Factor X Variant Corrects Hemostasis in a Mouse Model for Hemophilia A.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.